Genmab A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical and healthcare sectors, understanding the financial strategies of key players is crucial. Genmab A/S and Lantheus Holdings, Inc. offer a fascinating study in contrasts when it comes to their Selling, General, and Administrative (SG&A) expenses over the past decade.

From 2014 to 2023, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%, from approximately $80 million to nearly $3.3 billion. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Lantheus Holdings, Inc. has maintained a more conservative growth trajectory, with SG&A expenses increasing by around 270% during the same period, reaching approximately $267 million in 2023.

This divergence highlights differing strategic priorities: Genmab's focus on scaling operations versus Lantheus's steady, controlled growth. As these companies continue to evolve, their SG&A spending patterns will remain a key indicator of their strategic directions.